Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

A number of other equities research analysts have also recently issued reports on the company. BMO Capital Markets started coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating for the company. Royal Bank of Canada started coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating and a $23.00 target price for the company. Wedbush started coverage on Aquestive Therapeutics in a research report on Wednesday, September 12th. They set an outperform rating and a $33.00 target price for the company. Finally, JMP Securities began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating and a $29.00 target price for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $29.00.

Aquestive Therapeutics stock traded down $0.07 during trading hours on Wednesday, reaching $16.81. 27,765 shares of the company were exchanged, compared to its average volume of 122,998. The company has a quick ratio of 3.42, a current ratio of 3.63 and a debt-to-equity ratio of 1.88. Aquestive Therapeutics has a 12 month low of $13.61 and a 12 month high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.15). The business had revenue of $13.27 million during the quarter, compared to analysts’ expectations of $14.75 million. On average, analysts predict that Aquestive Therapeutics will post -1 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of AQST. Crestline Management LP bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $201,422,000. Perceptive Advisors LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $20,137,000. Alliancebernstein L.P. bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $14,323,000. BlackRock Inc. bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $8,254,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $5,305,000. 1.35% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Featured Story: Fiduciary

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.